Navigation Links
Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
Date:1/27/2011

CARY, N.C., Jan. 27, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study. This achievement solidifies Cetero's position as the unmatched leader in early-phase clinical development and highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology and generic clients.

"We are very proud of this extraordinary accomplishment, which has been made possible by our dedicated staff and loyal clients," said Troy W. McCall, PhD, Chief Executive Officer of Cetero. "One of the best measures of a CRO's capabilities is its depth and breadth of experience. Cetero can offer clients more efficient clinical studies and assurance of high-quality data on time as a result of having more early-phase experience than any other CRO."  

In conducting 20,000 studies over the past 30 years, Cetero has developed considerable experience with normal healthy participants, special populations and patients. Through targeted recruitment strategies and a constantly updated database, Cetero currently delivers a 99 percent on-time recruitment rate.

"Twenty-thousand studies is a significant achievement and truly reflects Cetero's strengths in conducting both traditional clinical trials with normal healthy participants and specialty Phase I and IIa trials with patients," said Alan Copa, PharmD, President, Clinical Operations - Fargo of Cetero. "Cetero's expertise across a wide range of therapeutic areas provides us with insights on drug development strategies in addition to efficient study execution."

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With nearly 30 years of experience from its founding companies, Cetero has conducted more than 20,000 clinical pharmacology studies - more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, normal healthy clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
2. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
3. Cetero Research Leads Industry in Human Allergy Models
4. Profil Institutes CEO Presenting on Early Phase Clinical Research in India
5. AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedys Disease)
6. IRBNet Announces Release of National Research Network™ 2010 Benchmark Report
7. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
8. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
9. Independent Clinical Research Confirms Clinical Efficacy and Cost-Effectiveness of the SurgiCount Safety-Sponge® System
10. Best Practices, LLC Research Highlights Critical Role of Medical Affairs in New Product Launch Success
11. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition of the "Oesophageal ... their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis and Strategies - ... Cancer market. The research answers the following questions: ... Oesophageal Cancer and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
(Date:2/23/2017)... , February 23, 2017 ... from increasing caseload for varicose veins in their body. ... globe are prompting the adoption of endovenous laser therapy ... global endovenous laser therapy market, published by ... of lifestyle choices and consequences of obesity have collectively ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, ... the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the ... April 10. Dr. Bell comes to Liberty from the Ohio University Heritage College ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
Breaking Medicine News(10 mins):